{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T11:51:41Z","timestamp":1783338701574,"version":"3.54.6"},"reference-count":40,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T00:00:00Z","timestamp":1548806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T00:00:00Z","timestamp":1548806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2019,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To explore the ocular distribution of bimatoprost after intracameral administration of a biodegradable sustained-release bimatoprost implant (Bimatoprost SR) versus repeated topical administration of bimatoprost 0.03% ophthalmic solution in dogs. Bimatoprost SR and topical bimatoprost 0.03% previously were shown to have similar intraocular pressure-lowering effects in humans in a phase 1\/2 clinical trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Twenty-four beagle dogs received either once-daily topical bimatoprost 0.03% for 7 days or a bilateral intracameral administration of Bimatoprost SR (15\u2009\u03bcg). At predetermined time points, ocular tissues were collected and concentrations of bimatoprost and bimatoprost acid were quantified using liquid chromatography\u2013tandem mass spectrometry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Bimatoprost SR administration enhanced delivery of study drug to a site of action [iris\u2013ciliary body (ICB)] compared with topical bimatoprost (\n                      <jats:italic toggle=\"yes\">C<\/jats:italic>\n                      <jats:sub>max<\/jats:sub>\n                      [bimatoprost+bimatoprost acid]\u2009=\u200918,200 and 4.13\u2009ng\/g, respectively). However, distribution of drug to tissues associated with prostaglandin analog (PGA)-related side effects (i.e., bulbar conjunctiva, eyelid margins, and periorbital fat) was limited following Bimatoprost SR administration (\n                      <jats:italic toggle=\"yes\">C<\/jats:italic>\n                      <jats:sub>max<\/jats:sub>\n                      [bimatoprost+bimatoprost acid]\u2009=\u2009BLQ [beneath the limit of quantitation] to 0.354\u2009ng\/g) compared with topical dosing (\n                      <jats:italic toggle=\"yes\">C<\/jats:italic>\n                      <jats:sub>max<\/jats:sub>\n                      [bimatoprost+bimatoprost acid]\u2009=\u200936.6\u20132,110\u2009ng\/g).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Bimatoprost SR administration in dogs selectively delivered drug to the ICB with low or undetectable drug levels in ocular surface and extraocular tissues. Use of Bimatoprost SR for glaucoma treatment may reduce the incidence of adverse events typically associated with topical PGAs by targeting bimatoprost delivery to the key site of action of the PGA class and reducing exposure to off-target tissues.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jop.2018.0067","type":"journal-article","created":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T15:13:32Z","timestamp":1539875612000},"page":"50-57","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":82,"title":["Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues"],"prefix":"10.1177","volume":"35","author":[{"given":"Jennifer R.","family":"Seal","sequence":"first","affiliation":[{"name":"Allergan plc, Irvine, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Robinson","sequence":"additional","affiliation":[{"name":"Allergan plc, Irvine, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Burke","sequence":"additional","affiliation":[{"name":"Allergan plc, Irvine, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Bejanian","sequence":"additional","affiliation":[{"name":"Allergan plc, Irvine, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Coote","sequence":"additional","affiliation":[{"name":"Center for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayssa","family":"Attar","sequence":"additional","affiliation":[{"name":"Allergan plc, Irvine, California."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,1,30]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.2012.02773.x"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2005.081224"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2012.02.003"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a017236"},{"key":"e_1_3_3_6_2","unstructured":"American Academy of Ophthalmology. Primary open-angle glaucoma PPP -. 2015. Available at www.aao.org\/preferred-practice-pattern\/primary-open-angle-glaucoma-ppp-2015 (last accessed December9 2016)."},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.613923"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0b013e3181666557"},{"key":"e_1_3_3_9_2","first-page":"447","article-title":"Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis","volume":"3","author":"Eyawo O.","year":"2009","unstructured":"Eyawo O., , Nachega J., , Lefebvre P., et al. Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis. Clin. Ophthalmol. 3:447\u2013456, 2009.","journal-title":"Clin. Ophthalmol"},{"key":"e_1_3_3_10_2","unstructured":"Lumigan\u00ae (Bimatoprost) prescribing information. Available at www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022184s000lbl.pdf (last accessed January3 2017)."},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S4163"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S23780"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/OPX.0000000000000009"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-011-9468-2"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.03.026"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2010.01862.x"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/112067210801800315"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(99)00528-X"},{"key":"e_1_3_3_19_2","first-page":"51","article-title":"Prostaglandin-associated periorbitopathy in latanoprost users","volume":"9","author":"Nakakura S.","year":"2015","unstructured":"Nakakura S., , Yamamoto M., , Terao E., et al. Prostaglandin-associated periorbitopathy in latanoprost users. Clin. Ophthalmol. 9:51\u201356, 2015.","journal-title":"Clin. Ophthalmol"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-010-0159-x"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2016.11.020"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/vop.12011"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(01)00224-7"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S44708"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.05.013"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.6.1.45"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0b013e31817d81df"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095461"},{"key":"e_1_3_3_29_2","unstructured":"Goldberg I. Laganovska G. Baumane K. et al. American Academy of Ophthalmology. 2014 18\u201321 October Chicago IL. Abstract PO390."},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.04.026"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2008.08.010"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/vop.12522"},{"key":"e_1_3_3_33_2","unstructured":"Craven E.R. Walters T.R. Christie W.C. et al. Presented at the American Academy of Ophthalmology Annual Meeting November 11\u201314 2017 New Orleans LA."},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.02-1281"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(97)80008-2"},{"key":"e_1_3_3_36_2","first-page":"757","volume-title":"A Comprehensive Guide to Toxicology in Nonclinical Drug Development, Second Edition","author":"Ferrell Ramos M.","year":"2016","unstructured":"Ferrell Ramos M., , Attar M., , Stern M.E., et al. Safety evaluation of ocular drugs. In: Faqi AS, ed. A Comprehensive Guide to Toxicology in Nonclinical Drug Development, Second Edition. London, UK: Academic Press; 2016; pp. 757\u2013811."},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.047837"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2011.0097"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(97)80007-0"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706044"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2004.08.019"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2018.0067","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2018.0067","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2018.0067","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:42:41Z","timestamp":1777646561000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2018.0067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,30]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2,1]]}},"alternative-id":["10.1089\/jop.2018.0067"],"URL":"https:\/\/doi.org\/10.1089\/jop.2018.0067","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,30]]}}}